JP2024520861A5 - - Google Patents

Info

Publication number
JP2024520861A5
JP2024520861A5 JP2023577141A JP2023577141A JP2024520861A5 JP 2024520861 A5 JP2024520861 A5 JP 2024520861A5 JP 2023577141 A JP2023577141 A JP 2023577141A JP 2023577141 A JP2023577141 A JP 2023577141A JP 2024520861 A5 JP2024520861 A5 JP 2024520861A5
Authority
JP
Japan
Prior art keywords
seq
compound
isovaleric acid
palm
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023577141A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520861A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/033378 external-priority patent/WO2022266060A1/en
Publication of JP2024520861A publication Critical patent/JP2024520861A/ja
Publication of JP2024520861A5 publication Critical patent/JP2024520861A5/ja
Pending legal-status Critical Current

Links

JP2023577141A 2021-06-14 2022-06-14 遺伝性ヘモクロマトーシスの治療のためのヘプシジン模倣体 Pending JP2024520861A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163210453P 2021-06-14 2021-06-14
US63/210,453 2021-06-14
US202163252001P 2021-10-04 2021-10-04
US63/252,001 2021-10-04
US202263349841P 2022-06-07 2022-06-07
US63/349,841 2022-06-07
PCT/US2022/033378 WO2022266060A1 (en) 2021-06-14 2022-06-14 Hepcidin mimetics for treatment of hereditary hemochromatosis

Publications (2)

Publication Number Publication Date
JP2024520861A JP2024520861A (ja) 2024-05-24
JP2024520861A5 true JP2024520861A5 (cg-RX-API-DMAC10.html) 2025-06-23

Family

ID=84527344

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023577141A Pending JP2024520861A (ja) 2021-06-14 2022-06-14 遺伝性ヘモクロマトーシスの治療のためのヘプシジン模倣体

Country Status (11)

Country Link
US (1) US20240293511A1 (cg-RX-API-DMAC10.html)
EP (2) EP4355763A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024520861A (cg-RX-API-DMAC10.html)
KR (1) KR20240021833A (cg-RX-API-DMAC10.html)
AU (1) AU2022293672A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023026381A2 (cg-RX-API-DMAC10.html)
CA (1) CA3220871A1 (cg-RX-API-DMAC10.html)
IL (1) IL309166A (cg-RX-API-DMAC10.html)
MX (1) MX2023015021A (cg-RX-API-DMAC10.html)
TW (1) TW202317604A (cg-RX-API-DMAC10.html)
WO (1) WO2022266060A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
CA2949215C (en) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
MX2022008740A (es) 2020-01-15 2022-09-23 Janssen Biotech Inc Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
SMT202500254T1 (it) 2020-01-15 2025-09-12 Janssen Biotech Inc Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
KR20240034224A (ko) 2021-07-14 2024-03-13 얀센 바이오테크 인코포레이티드 인터류킨-23 수용체의 지질화된 펩티드 억제제
WO2025207760A1 (en) * 2024-03-27 2025-10-02 Protagonist Therapeutics, Inc. Formulations of a hepcidin peptide analogue

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
KR20170002414A (ko) 2014-04-07 2017-01-06 멀겐져 바이오텍, 아이엔씨. 헵시딘 모방 펩티드 및 그 용도
AU2015279571A1 (en) * 2014-06-27 2017-02-02 Protagonist Therapeutics, Inc. Hepcidin and mini-hepcidin analogues and uses therof
WO2016109363A1 (en) * 2014-12-29 2016-07-07 The Regents Of The University Of California S-Alkylated Hepcidin Peptides and Methods of Making and Using Thereof
WO2017068089A2 (en) 2015-10-23 2017-04-27 Vifor (International) Ag Novel ferroportin inhibitors
CA3009834A1 (en) * 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
AU2017324446A1 (en) 2016-09-06 2019-03-28 La Jolla Pharmceutical Company Methods of treating iron overload
WO2018128828A1 (en) 2016-12-23 2018-07-12 Bayer Healthcare Llc Novel hepcidin mimetics and uses thereof
US20220372099A1 (en) * 2019-09-03 2022-11-24 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics

Similar Documents

Publication Publication Date Title
JP2025163134A5 (cg-RX-API-DMAC10.html)
JP2022546878A5 (cg-RX-API-DMAC10.html)
US12269856B2 (en) Hepcidin analogues and uses thereof
JP2024520861A (ja) 遺伝性ヘモクロマトーシスの治療のためのヘプシジン模倣体
EP1121155B1 (en) Site-directed dual pegylation of proteins
JP2025163134A (ja) コンジュゲートされたヘプシジン模倣物
JP2003522721A5 (cg-RX-API-DMAC10.html)
US7452865B2 (en) Antagonistic analogs of GH RH (2003)
CN101983068B (zh) N末端和c末端取代的人gh-rh拮抗类似物
JP2025519535A (ja) 鎌状赤血球病の治療のためのヘプシジン模倣体
WO2024011188A1 (en) Combination therapy for treatment of iron overload diseases
TW585873B (en) Antagonistic analogs of GH-RH inhibiting IGF-I and -II
JPH0753591A (ja) 胃腸運動活性を抑制するモチリン類似ポリペプチド
CA2337667C (en) Dextran-leptin conjugates, pharmaceutical compositions and related methods
EP3094643B1 (en) Lipidated peptides for lowering blood glucose
KR100240434B1 (ko) 구조적으로 변형된 혈관작용성 소장 펩티드(vip)의 유도체 및 이를 함유한 제약 조성물
JPH0770178A (ja) 胃腸運動刺激活性を有するモチリン類似ポリペプチド
CN117480176A (zh) 用于治疗遗传性血色病的铁调素模拟物
HK1220112B (en) Hepcidin analogues and uses therof